AIM says first patient dosed with Ampligen in study evaluating it as drug combo to treat patients with cancer and COVID-19

AIM ImmunoTech Inc (NYSEAMERICAN:AIM) (FRA:HXB2) said on Wednesday that it had achieved a milestone in its coronavirus (COVID-19) treatment and prevention efforts with the first patient dosed in a study evaluating its lead drug Ampligen as part of a combination treatment for patients with cancer and COVID-19.  The Ocala, Florida-based company said that Roswell Park Comprehensive Cancer Center’s Phase 1/2a study evaluating the two-drug combo of AIM’s Ampligen and interferon alpha-2b as a potential early-onset treatment for patients with cancer and mild-to-moderate COVID-19 is “fully underway, with the first patient enrolled and treated on the study.”  AIM is a collaborator on that clinical trial, which is funded in part through grants from the National Cancer Institute and AIM, as well as institutional support from Roswell Park. AIM said it is providing Ampligen at no charge for the study. More details about this trial, led by Roswell Park co-Principal Investigators, Dr Brahm Segal and Dr Pawel Kalinski, are available at ClinicalTrials.gov.  READ: AIM ImmunoTech trumpets $54.5M in cash on hand, advances its drug Ampligen as cancer, coronavirus treatment In addition, AIM is working to develop an intranasal prophylaxis strategy for frontline workers, the elderly and other high-risk patients, including those with co-morbidities such as cancer. The company has also devoted itself to working on an effective therapy for COVID-19 long haulers, a portion of people who are diagnosed with the disease still suffer persistent and debilitating symptoms months later. In a statement, AIM CEO Thomas K Equels said: “While major global pharmaceutical companies have largely focused their efforts on the critical need for a COVID-19 vaccine – with Moderna and Pfizer recently announcing significant and hopeful results – AIM believes there is an equally critical health need to develop an early-onset treatment for people already infected with the disease.” “We greatly appreciate the leadership of Dr Brahm Segal and Dr Pawel Kalinski, as well as the tremendous efforts of the entire team at Roswell Park. We look forward to providing further updates as this critical trial progresses.” AIM ImmunoTech is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19. Contact the author Uttara Choudhury at uttara@proactiveinvestors.com Follow her on Twitter: @UttaraProactive